Well StudiedWeight LossGrowth Hormone

Sermorelin

Sermorelin acetate

GHRH Analog | Growth Hormone Releasing Hormone

Half-life

10-12 minutes

Chain length

29 amino acids

Reference frequency

Once daily at bedtime (aligns with natural GH pulse)

Research overview

DoseGear research brief

Sermorelin is a synthetic 29-amino acid analog of human growth hormone-releasing hormone that stimulates natural growth hormone production while preserving physiological pulsatile patterns. Originally FDA-approved in 1997 for pediatric GH deficiency, it was discontinued in 2008 for manufacturing reasons, not safety concerns.

Mechanism of action

Subcutaneous injection provides optimal bioavailability for binding GHRH receptors, stimulating pulsatile GH release while maintaining hypothalamic-pituitary axis integrity and allowing natural somatostatin negative feedback.

Compound background

Development & research timeline

Study windows describe what researchers measured, not when an individual should expect a result.

Origin & development

Synthetic GHRH(1–29) analog formerly marketed for pediatric growth-hormone-related indications.

What it is researched for

Growth-hormone secretion and growth-deficiency research through pituitary GHRH-receptor activation.

Research observation window

A subcutaneous pediatric study assessed growth at six months; adult studies used 14 days or four months.

Reference data

Lyophilized vial injectable protocols

Not personalized dosing instructions

Only injectable vial references are shown. Nasal, topical, and unsupported non-vial schedules are excluded.

Research context	Amount	Frequency	Route
Anti-aging/Longevity	200-300mcg	Once at bedtime	SubQ
Athletic Performance	300-500mcg	Once at bedtime	SubQ
Body Composition	200mcg	5 days weekly	SubQ
Combination Therapy	200mcg + GHRP	Once daily	SubQ co-injection

Reference cycle

3-6 months continuous

Reference storage

Reconstituted: 2-8°C, use within 10-30 days

Safety context

Reported side effects

Injection site reactions (16.7% of patients - generally mild)
Nasal irritation (intranasal route)

Contraindications & cautions

Active malignancy
Pituitary tumors
Pregnancy

Scientific references

01
The effects of intranasal insufflation of growth hormone releasing factor analogue GRF 1-29 NH2 on growth hormone secretion in children with short stature
Scientific citationThe effects of intranasal insufflation of growth hormone releasing factor analogue GRF 1-29 NH2 on growth hormone secretion in children with short stature. Clinical Endocrinology (1988).
02
Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men
Scientific citationGrowth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. Journal of Clinical Endocrinology & Metabolism (1992).
03
Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy
Scientific citationOnce daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Journal of Clinical Endocrinology & Metabolism (1996).
04
Endocrine and metabolic effects of long-term administration of [Nle27 ]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women
Scientific citationEndocrine and metabolic effects of long-term administration of [Nle27 ]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. Journal of Clinical Endocrinology & Metabolism (1997).

This DoseGear profile combines published scientific literature with lyophilized-vial protocol references. Citations are provided for independent review.

Related research profiles

Growth Hormone